文献类型： 外文期刊

作者： Fu, Qiuling ¹ ; Han, Xiangmin ² ; Zhu, Chunhua ³ ; Jiao, Wenlong ¹ ; Liu, Rongchang ¹ ; Feng, Zhao ³ ; Huang, Yaping ⁴ ; Chen, Zhen ¹ ; Wan, Chunhe ¹ ; Lai, Zhi ² ; Liang, Qizhang ¹ ; Shi, Shaohua ¹ ; Cheng, Longfei ¹ ; Chen, Hongmei ¹ ; Jiang, Nansong ¹ ; Su, Jingliang ⁵ ; Fu, Guanghua ¹ ; Huang, Yu ¹ ;

作者机构： 1.Fujian Ind Technol Innovat Res Acad Livestock & Po, Fujian Acad Agr Sci, Inst Anim Husb & Vet Med, Fujian Key Lab Control & Prevent Avian Dis, Fuzhou 350013, Peoples R China

2.Shanghai Chuanghong Biotech Co Ltd, Shanghai 201619, Peoples R China

3.Sinopharm Anim Hlth Corp Ltd, Wuhan 430075, Peoples R China

4.Minjiang Teachers Coll, Dept Chem & Biol Engn, Fuzhou 350108, Peoples R China

5.China Agr Univ, Coll Vet Med, Beijing 100193, Peoples R China

关键词： duck hepatitis A virus type 3 (DHAV-3); live attenuated vaccine candidate; genome analysis; protective efficacy

期刊名称：POULTRY SCIENCE （ 影响因子：3.8； 五年影响因子：4.1 ）

ISSN： 0032-5791

年卷期： 2024 年 103 卷 10 期

页码：

收录情况： SCI

摘要： Duck hepatitis A virus type 3 (DHAV-3) is an infectious virus that is highly fatal to ducklings and causes significant economic losses in the duck industry worldwide. Biosecurity and vaccination are required to control the pathogen. In the present study, we attenuated a lowly pathogenic DHAV-3 clinical isolate, named as HB, by serial passaging in duck embryos, and followed by several adaptive proliferations in specific-pathogen-free (SPF) chicken embryos. The virulence of DHAV-3 at different passages was assessed by infecting 3-day-old ducklings. We found that the HB strain lost pathogenicity to ducklings from the 55th passage onwards. The 80th passage strain (HB80), which achieved good growth capacity in duck embryos with a viral titer of 10 8.17 50% egg lethal dose per milliliter (ELD50/mL), 50 /mL), was selected as a live attenuated vaccine candidate. The HB80 strain did not induce clinical symptoms or pathological lesions in 3-day-old ducklings and showed no virulence reversion after 5 rounds of in vivo back-passage. The minimum effective dose of HB80 was determined to be 10 4.5 ELD50 50 by hypodermic inoculation of the neck. Importantly, a single dose of HB80 elicited good immune responses and provided complete protection against challenge with the lethal DHAV-3 strain. Compared with the genomic sequence of the parental HB strain, HB80 had 7 amino acid substitutions, two of them are in the hypervariable region of the VP1 and polymerase-encoding 3D regions, which may play a role in virulence attenuation. Our data suggest that the attenuated HB80 strain is a promising vaccine candidate for the prevention of DHAV-3 infections in China. HB80 has been registered as a New Veterinary Drug Registration Certificate by the Chinese Ministry of Agriculture and Rural Affairs (MARA), and is the first live attenuated DHAV-3 vaccine strain to be officially licensed in China.